Dose-dependent anemia has been observed with ruxolitinib treatment, with Hb levels reaching a nadir between 8 and 12 weeks after commencing treatment and returning to baseline by week 24 [23, 24]. This evidence concerns the gene GSTM1 and anemia (phenotype).